



July 31, 2015

Press release

Company : Fuji Pharma Co., Ltd
Code No.4554 Tokyo Stock Exchange, First Section
Representative Director : Hirofumi Imai,
President and CEO
TEL : +81-3-3556-3344

**Announcement of transfer of distribution and sales rights of
Magnescope[®], Hexabrix[®] and Lipiodol[®]**

Fuji Pharma Co., Ltd (hereinafter called “Fuji”) is pleased to announce its agreement with Guerbet Japan KK (hereinafter called “Guerbet”) whereby the distribution and sales rights of Magnescope[®], Hexabrix[®] and Lipiodol[®] will be transferred to Fuji from October 2, 2015.

After the transfer hereinabove, Fuji takes the responsibility for supplying these three products and collecting and providing products’ information; while, Guerbet holds marketing authorization rights.

By adding these three products to the existing portfolio in the contrast media field, e.g. Optiray[®] transferred from Mallinckrodt Japan Co., Ltd in June 2014 and other generic products, Fuji covers the major contrast medium fields in X-ray and MRI from branded products to generic products and will be able to support even more patients and hospitals in the diagnostic imaging, interventional treatment, radiology, oncology and fertility treatment fields.

We will maximize our corporate value with efficient sales activities mixed up with branded products, biosimilars and generic products in acute therapy fields.

[Product outline]

Product name	Active ingredient	Character
Magnescope [®] 38% Syringe10mL Magnescope [®] 38% Syringe11mL Magnescope [®] 38% Syringe13mL Magnescope [®] 38% Syringe15mL Magnescope [®] 38% Syringe20mL	Meglumine gadoterate	MRI imaging, distributed outside of Japan under the name Dotarem [®] , leading contrast agent in Europe.
Hexabrix [®] 320 20mL Hexabrix [®] 320 50mL Hexabrix [®] 320 100mL	Ioxaglic acid	X-ray imaging contrast media and a specialty contrast medium in neuro and cardiovascular imaging and interventional radiology.
Lipiodol [®] 480 10mL	Ethyl ester of iodinated poppy-seed oil fatty acid	For the treatment by conventional transarterial chemoembolization (eTACE) of tumors in adults with known, intermediate-stage hepatocellular carcinoma (HCC) and for hysterosalpingography in infertility treatment.

(For these three products, no generic products are marketed in Japan.)